Bio-Rad Laboratories, Inc. (NYSE:BIO) stock has seen significant action in the market, with varied sentiment expressed by market participants, financial institutions, and analysts. Wedge Capital Management L L P NC and Contravisory Investment Management Inc. have respectively acquired 87,487 and 1,731 Bio-Rad shares and Principal Financial Group Inc. also increased their position. However, JPMorgan Chase & Co. sold 4,840 shares and Captrust Financial Advisors also decreased their holdings. Tidal Investments LLC and Janus Henderson Group PLC also reduced their position. On the bearish side, Bio-Rad shareholders have witnessed a 58% loss, with the stock dipping 4.6% in the past week and declining 14% in another week, accruing a three-year loss of 53%. On the bullish side, corresponding to its robust financial performance, Bio-Rad's stock has surged, recently hitting a 52-week high of $365.65. In addition, the Royal Bank of Canada has reaffirmed their 'Outperform' rating for BIO and GAMMA Investing LLC purchased 130 shares. While Bio-Rad has revised its annual revenue forecast due to weak demand for diagnostic products, its Q3 results exceeded estimates. The question is raised on whether Bio-Rad is potentially undervalued, with analysts giving it an average PT of $394.20.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Sat, 18 Jan 2025 20:49:12 GMT -
Rating 1
- Innovation -3
- Information 4
- Rumor -5
